[Pharmacokinetics of dioxonium]

Area of Science:

• Pharmacology
• Pharmacokinetics
• Drug Metabolism

Background:

• Peripheral muscle relaxants are crucial in anesthesia and critical care.
• Understanding the pharmacokinetic profile of new agents like dioxonium is essential for safe and effective use.

Purpose of the Study:

• To investigate the pharmacokinetics of dioxonium, a novel peripheral muscle relaxant.
• To determine the relationship between dioxonium blood plasma levels and the cessation of muscle relaxation (curarization).
• To identify the primary routes of dioxonium excretion and its form in the organism.

Main Methods:

• Intravenous administration of carbon-14 labeled dioxonium (dioxonium-C14) in rats.
• Measurement of radioactivity in blood plasma over time.
• Analysis of radioactivity distribution in major organs and tissues.
• Identification of excreted drug forms.

Main Results:

• Intravenous dioxonium-C14 administration resulted in biphasic changes in blood plasma radioactivity.
• Curarization ceased at a consistent blood plasma radioactivity level, independent of the administered dioxonium dose.
• Highest radioactivity concentrations were found in skeletal muscles and kidneys.
• Dioxonium is eliminated from the organism via the kidneys in its unchanged, pharmacologically active form.

Conclusions:

• Dioxonium exhibits predictable pharmacokinetics with a defined endpoint for its muscle relaxant effect.
• The kidneys are the primary route for the elimination of active dioxonium.
• These findings are critical for optimizing the clinical application of dioxonium.